表紙
市場調查報告書
商品編碼
914618

化膿性汗腺炎:機會分析與預測 (∼2028年)

Hidradenitis Suppurativa: Opportunity Analysis and Forecasts to 2028

出版日期: | 出版商: GlobalData | 英文 83 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

2018年的化膿性汗腺炎 (HS)的銷售額規模在主要7個國家 (美國、法國、德國、義大利、西班牙、英國、日本) 估計約8億9800萬美元。

本報告提供主要7個國家的化膿性汗腺炎 (HS) 市場相關調查,市場形勢的變化,最有前途的後期階段的開發平台藥物,最大的未滿足需求,HS形勢的最大機會,銷售額的十年預測等資訊分析。

第1章 目錄

第2章 化膿性汗腺炎 (HS):摘要整理

  • 新加入企業促進主要7個市場中緩慢的成長
  • 開發平台治療藥的開始販售引起HS形勢的變化
  • 在HS市場上未滿足需求高,尤其是在效果高的治療中
  • 開發平台藥物對目前治療藥提供漸進性的改善
  • 醫生的想法是什麼?

第3章 簡介

第4章 疾病概要

  • 病因、病理學
  • 分類或分期

第5章 流行病學

  • 疾病的背景
  • 風險因素、合併症
  • 全球趨勢、歷史性的趨勢
    • 美國
    • EU5個國家
  • 預測手法
  • HS的流行病學的預測
  • 討論

第6章 目前治療選擇

  • 概要
  • 診斷
  • 治療方法

第7章 未滿足需求、機會的評估

  • 概要
  • 有效的治療方法的附錄
  • HS的早期診斷
  • 纖維症的治療選擇的不足
  • HS的整體管理的不足

第8章 R&D策略

  • 概要
  • 臨床實驗設計

第9章 開發平台評估

  • 概要
  • 創新的早期階段的方法

第10章 開發平台評估分析

  • 主要開發平台藥物臨床基準
  • 主要開發平台藥物的商業基準
  • 競爭評估
  • 銷售額的十年預測
    • 美國
    • EU5個國家
    • 日本

第11章 附錄

目錄
Product Code: GDHC098POA

Hidradenitis Suppurativa (HS) is a chronic, inflammatory, debilitating skin disease that is characterized by the recurrent development of painful nodules and abscesses that rupture. This leads to the formation of sinus tracts and scarring on the skin. The exact cause of HS is unknown, and it is hypothesized that genetic and environmental factors are the key causes of the disease Environmental factors such as smoking, obesity, and being overweight are considered to be trigger factors in HS development. Additionally, genetic factors are also believed to play a key role in the development of HS. DNA studies have revealed that approximately one-third of patients with HS have a family history of HS. Studies have also shown that there are inheritance patterns within families who are affected by HS.

GlobalData estimates the 2018 sales for the HS market at approximately $898 million across the 7MM, encompassing the US, the five major European Union countries (5EU: France, Germany, Italy, Spain, and UK) and Japan. Over the course of the 10-year forecast period, the HS market will grow at a Compound Annual Growth Rate (CAGR) of 7.2% across the 7MM. Each of the 7MM are anticipated to grow significantly, recording CAGRs of 9.9%, 1.2% and -0.5% across the US, 5EU and Japan, respectively. At the end of 2028, the US will account for 79.1% of sales across the 7MM, while the 5EU and Japan will account for around 20.9% of sales. The higher sales numbers for the US can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of HS in the region, as well as the anticipated high annual cost of therapy (ACOT) of biologics in the US market.

Key Questions Answered:

  • How will the HS market landscape in the 7MM (US, France, Germany, Italy, Spain, UK and Japan) change from 2018-2028?
  • What are the most promising late-stage pipeline drugs in HS?
  • How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
  • What are the greatest unmet needs in HS? Will the pipeline drugs fulfil these needs of the market?
  • What are the largest opportunities in the HS landscape?

Scope:

  • Overview of HS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline HS market revenue from 2018-2028. ACOT and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HS therapeutics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global HS therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy:

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global HS therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HS therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Hidradenitis Suppurativa: Executive Summary

  • 2.1. New Entrants Will Drive Modest Growth Across the 7MM from 2018 to 2028
  • 2.2. Launch of Pipeline Therapies Will Lead to Change in the HS Landscape
  • 2.3. High Unmet Needs Exists in the HS Market, Especially for a Highly Efficacious Treatment
  • 2.4. Pipeline Agents Will Offer Incremental Improvements Over Current Therapies
  • 2.5. What Do Physicians Think?

3. Introduction

  • 3.1. Catalyst
  • 3.2. Related Reports
  • 3.3. Upcoming Related Reports

4. Disease Overview

  • 4.1. Etiology and Pathophysiology
    • 4.1.1. Etiology
    • 4.1.2. Pathophysiology
  • 4.2. Classification or Staging Systems

5. Epidemiology

  • 5.1. Disease Background
  • 5.2. Risk Factors and Comorbidities
  • 5.3. Global and Historical Trends
    • 5.3.1. US
    • 5.3.2. 5EU
  • 5.4. Forecast Methodology
    • 5.4.1. Sources
    • 5.4.2. Forecast Assumptions and Methods
  • 5.5. Epidemiological Forecast for HS (2018-2028)
    • 5.5.1. Diagnosed Active Prevalent Cases of HS
    • 5.5.2. Age-Specific Diagnosed Active Prevalent Cases of HS
    • 5.5.3. Sex-Specific Diagnosed Active Prevalent Cases of HS
    • 5.5.4. Diagnosed Active Prevalent Case of HS by Severity
    • 5.5.5. Diagnosed Active Prevalent Cases of HS with IBD
  • 5.6. Discussion
    • 5.6.1. Epidemiological Forecast Insight
    • 5.6.2. Limitations of the Analysis
    • 5.6.3. Strengths of the Analysis

6. Current Treatment Options

  • 6.1. Overview
  • 6.2. Diagnosis
  • 6.3. Treatment

7. Unmet Needs and Opportunity Assessment

  • 7.1. Overview
  • 7.2. Lack of Efficacious Treatment
  • 7.3. Early Diagnosis of HS
  • 7.4. Lack of Treatment Options for Fibrosis
  • 7.5. Lack of Holistic Management of HS

8. R&D Strategies

  • 8.1. Overview
    • 8.1.1. Biological Therapies
    • 8.1.2. Oral Therapies
  • 8.2. Clinical Trial Design
    • 8.2.1. Current Clinical Trial Design
    • 8.2.2. Limitations and Future Outlook

9. Pipeline Assessment

  • 9.1. Overview
  • 9.2. Innovative Early-Stage Approaches

10. Pipeline Valuation Analysis

  • 10.1. Clinical Benchmark of Key Pipeline Drugs
  • 10.2. Commercial Benchmark of Key Pipeline Drugs
  • 10.3. Competitive Assessment
  • 10.4. Top-Line 10-Year Forecast
    • 10.4.1. US
    • 10.4.2. 5EU
    • 10.4.3. Japan

11. Appendix

  • Disclaimer

List of Tables

  • Table 1: Hidradenitis Suppurativa: Key Metrics in the 7MM
  • Table 2: Classification of Hidradenitis Suppurativa
  • Table 3: Risk Factors and Comorbidities for Hidradenitis Suppurativa
  • Table 4: Treatment Guidelines for HS
  • Table 5: Leading Treatments for Hidradenitis Suppurativa, 2019
  • Table 6: Clinical Trial Design for HS Pipeline Agents in Late-Stage Development, 2018
  • Table 7: Innovative Early-Stage Approaches for Hidradenitis Suppurativa, 2018
  • Table 8: Clinical Benchmark of Key Pipeline Drugs - HS, 2018
  • Table 9: Commercial Benchmark of Key Pipeline Drugs - Hidradenitis Suppurativa, 2018
  • Table 10: Key Events Impacting Sales for HS, 2018-2028
  • Table 11: Hidradenitis Suppurativa Market - Global Drivers and Barriers, 2018-2028.
  • Table 12: Key Historical and Projected Launch Dates for HS
  • Table 13: Key Historical and Projected Patent Expiry Dates for HS
  • Table 14: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales Forecast by Country for HS in 2018 and 2028
  • Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Humira
  • Figure 3: Pathophysiology of Hidradenitis Suppurativa
  • Figure 4: Diagnosed Active Prevalence of HS, 7MM, Men and Women, Ages ≥18 Years, 2018, (%)
  • Figure 5: Sources Used and Not Used for Diagnosed Active Prevalence of HS
  • Figure 6: Sources Used for Severity of HS
  • Figure 7: Sources Used for Digestive Comorbidities of HS
  • Figure 8: Diagnosed Active Prevalent Cases of HS, 7MM, Men and Women, Ages ≥18 Years, 2018, N
  • Figure 9: Age-Specific Diagnosed Active Prevalent Cases of HS, 7MM, Men and Women, Ages ≥18 Years, 2018, N
  • Figure 10: Sex-Specific Diagnosed Active Prevalent Cases of HS, 7MM, Men, Women, Ages ≥18 Years, 2018, N
  • Figure 11: Diagnosed Active Prevalent Cases of HS by Severity, 7MM, Men and Women, Ages ≥18 Years, 2018, N
  • Figure 12: Diagnosed Active Prevalent Cases of HS with IBD, 7MM, Men and Women, Ages ≥18 Years, 2018, N
  • Figure 13: Treatment Algorithm for HS
  • Figure 14: Unmet Needs and Opportunities in Hidradenitis Suppurativa
  • Figure 15: Overview of the Development Pipeline in HS
  • Figure 16: 7MM, Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to be Launched for HS During the Forecast Period
  • Figure 17: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Humira
  • Figure 18: Global (7MM) Sales Forecast, by Country, for HS in 2018 and 2028
  • Figure 19: Global Sales Forecast by Class for HS in 2018 and 2028
  • Figure 20: Sales Forecast by Class for HS in the US in 2018 and 2028
  • Figure 21: Sales Forecast by Class for HS in the 5EU in 2018 and 2028
  • Figure 22: Sales Forecast by Class for HS in Japan in 2018 and 2028